-
-
The DCIS DilemmaDuctal carcinoma in situ is the fourth most common cancer diagnosis in women. Some say it's not "really" cancer. But you wouldn't know that based on how it is treated.
by Sue Rochman
-
Healthy Habits
Reaping the BenefitsFollowing a vegetarian diet could reduce your risk of colorectal cancer.
by Leigh Labrie
-
Q&A
The Language of CancerResearcher David J. Hauser discusses how war metaphors may make people less likely to engage in preventive behaviors.
by Sharlene George
-
Preserving the FutureYoung adults undergoing cancer treatment who may want to have children should talk with their doctors about ways to preserve their fertility.
by Marci A. Landsmann
-
From the Editor-in-Chief
Inheritance, ‘Bad Luck’ and the EnvironmentWhy do some people develop cancer while others do not?
by William G. Nelson, MD, PhD
-
Forward Look
There Goes the NeighborhoodQ&A with scientist Zena Werb on cancer, immunity and the microenvironment.
by Chris Palmer
-
From the Editor-in-Chief
The Promise of Precision MedicineThe impact of gene sequencing on the discovery and development of cancer treatments could be profound.
by William G. Nelson, MD, PhD
-
Forward Look
Genetic Testing Can Help Women With Triple-Negative Breast CancerStudy confirms inherited genetic mutations are common, regardless of family history.
by Kendall K. Morgan
-
Forward Look
Medicare to Cover Lung Cancer ScreeningIn high-risk current and former smokers, screening can reduce cancer deaths.
by Michael Eisenstein
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
